ERBB2 and breast carcinoma: Preclinical support for this trial comes from work by Priceman et al. published in 2017 evaluating the efficacy of IT and intratumoral CAR T cells with different intracellular costimulatory domains targeting HER2 positive breast cancer metastasis to the brain.